The nano formulation is expected to deliver the next generation bone cement with tailor-designed antibiotics release profiles and prolonged antibacterial activity. The key commercial advantages to potential bone cement manufacturers and end users are sustained antibiotics release, reduction in standard antibiotics dosage, minimised use of intravenous doses and creating new opportunities to use other benefit ingredient for local targeted delivery. Once commercialized, the socio-economic impact and savings in medical resources and costs are expected to be significant as the risk of post-operative infections can be reduced.